

Claims

We Claim:

1. A method of treating or preventing
intermittent claudication in a subject comprising the
5 step of administering a therapeutically effective amount
of GLP-1 molecule.

2. A method of treating or preventing
skeletal muscle injury caused by ischemia and/or
reperfusion in a subject comprising the step of
10 administering a therapeutically effective amount of GLP-1
molecule.

3. The method according to claim 1 or 2,
wherein the GLP-1 molecule is selected from the group
consisting of GLP-1(7-36)NH₂, GLP-4(7-37), and exendin-4.

4. The method according to claim 1 or 2,
wherein the GLP-1 molecule is selected from the group
consisting of GLP-1(7-36)NH₂ and GLP-1(9-36)NH₂.

5. The method according to claim 1 or 2,
wherein the subject is also administered free radical
20 scavengers.

6. The method according to claim 5, wherein
the free radical scavenger is selected from the group
consisting of glutathione, melatonin, Vitamin E, and
superoxide dismutase.

7. The method according to claim 1 or 2,
wherein the subject is also administered glucose.

8. The method according to claim 7, wherein
the subject is also administered potassium.

9. The method according to claim 1 or 2,
wherein the subject is suffering from PVD.

10. The method according to claim 1 or 2,
wherein the subject is human.

5 11. The method according to claim 1 or 2,
wherein the GLP-1 is administered by an infusion pump or
by subcutaneous injection of a slow release formulation.

10